AMIX
Autonomix Medical, Inc.0.6320
-0.0310-4.68%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.37MP/E (TTM)
-Basic EPS (TTM)
-4.51Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Autonomix Medical posted a Q3 FY2026 operating loss of $3.3M, up 22% y/y from $2.7M, driven by 65% higher R&D at $1.7M on clinical trials while G&A dipped 5% to $1.6M. YTD loss swelled to $14.3M from $8.3M, fueled by $3.7M in stock option cancellations (derived). No revenue yet; cash holds at $9.9M after $10.2M financing inflows offset $9.4M operating burn, funding into Q3 2026. Shares outstanding ballooned to 11.4M, diluting EPS to $(0.36) from $(1.46). Cash lasts one year. Nasdaq bid price lags below $1.
8-K
Nasdaq bid price deficiency
Autonomix Medical received a Nasdaq deficiency notice on January 14, 2026, for its common stock closing below $1.00 for 30 consecutive business days, violating the Bid Price Rule. It has 180 days until July 13 to sustain $1.00 closes for 10 straight business days. No immediate delisting. Reverse split looms if needed.
8-K
Rapid pain relief across stages
Autonomix unveiled subgroup data from its PoC study at the 2026 ASCO GI Symposium, showing rapid pain relief in pancreatic cancer patients across Stages 2-4. Within 24 hours, responders saw marked reductions; by 7 days, 93.75% (N=16) dropped to mild/moderate pain. Data holds durable through 3 months. Late-stage patients gained palliative relief despite progression risks.
8-K
Autonomix raises $5M via warrants
Autonomix Medical closed a $5.0 million private placement on November 19, 2025, selling pre-funded warrants for 4,501,666 shares at $0.001 and Series C warrants for 9,003,332 shares at $0.8607, exercisable immediately with the latter expiring in 5.5 years. Proceeds fund working capital amid ownership caps at 4.99-9.99%. Cash bolsters runway, yet dilutes on exercise.
10-Q
Q2 FY2026 results
Autonomix Medical posted a $7.5M operating loss for Q2 FY2026 ended September 30, 2025, up 166% y/y from $2.8M, driven by G&A expenses tripling to $5.2M on $3.7M accelerated stock-based comp from option cancellations while R&D doubled to $2.4M for clinical trials. Net loss hit $7.5M, matching operating with minor $0.1M interest income; YTD loss $10.8M (96% y/y rise), EPS $(1.38) on 5.4M shares (anti-dilutive). Cash burned $6.4M in ops (no capex), ending at $7.5M after $4.8M financing from ATM sales and warrant inducements; facilities like $15M Lincoln Park line remain untapped. Shares outstanding jumped to 6.2M. Cash lasts to Q3 2026.
APYX
Apyx Medical Corporation
3.72-0.07
AXGN
AxoGen, Inc.
29.35-0.43
BSX
Boston Scientific Corporation
92.95+0.76
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
3.10+0.06
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NXL
Nexalin Technology, Inc.
0.81-0.01
OFIX
Orthofix Medical Inc.
15.55-0.16
PMI
Picard Medical, Inc.
2.30-0.13
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00